Fedichev on Rapamycin: Claim Without Context
Peter Fedichev's texts cite rapamycin as a TOR inhibitor and as part of a combination that produced the greatest lifespan-extending effect, but the combination's composition and experimental model are not disclosed.
Peter Fedichev's texts name rapamycin (sirolimus, an FDA-approved immunomodulator) as an inhibitor of TOR. The same texts state that a rapamycin-containing combination produced the greatest lifespan-extending effect.
The composition of that combination is not disclosed. The other components, the experimental model, and the effect size are all unknown. The claim is there, but the supporting context is not.
Fedichev's page lists mTOR signaling and network theory of aging as related terms. Their proximity to rapamycin suggests that Fedichev's texts treat rapamycin as one element in a broader account of aging. That reading is a hypothesis: the text does not state it outright.
Two places to look next: the mTOR signaling page and the OpenDrugs project, which also investigates rapamycin.
The edge rests on two specific textual claims about rapamycin: its mechanistic role as a TOR inhibitor and its presence in the top-performing lifespan combination. The concrete gap (unknown combination components and experimental model) makes this worth surfacing rather than burying in a list of term associations.